

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jiangsu Recbio Technology Co., Ltd.**

### **江蘇瑞科生物技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2179)**

## **CHANGE OF DIRECTORS**

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

### **RESIGNATION OF DIRECTORS**

The board of directors of the Company (the “**Board**”) received resignation reports of Mr. Zhao Hui (“**Mr. Zhao**”) and Dr. Du Wei (“**Dr. Du**”) on March 20, 2023. Mr. Zhao and Dr. Du resigned from their positions as non-executive directors and members of the Remuneration and Appraisal Committee of the Board of the Company due to the change in their personal work arrangements. Pursuant to the relevant provisions of the Articles of Association of Jiangsu Recbio Technology Co., Ltd., the resignation reports of Mr. Zhao and Dr. Du take effect from the date on which the resignation reports are submitted to the Board.

Mr. Zhao and Dr. Du have confirmed that they have no disagreement with the Company and the Board, and there are no other matters relating to their resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company (the “**Shareholders**”).

The Company would like to take this opportunity to express its sincere gratitude to Mr. Zhao and Dr. Du for their contributions to the development of the Company during their tenure.

### **PROPOSED APPOINTMENT OF DIRECTORS**

The Board is pleased to announce that Mr. Zhang Jiaxin (“**Mr. Zhang**”) was nominated as a non-executive director of the Company and Ms. Chen Qingqing (“**Ms. Chen**”) was nominated as an executive director of the Company at the Board meeting held on March 20, 2023. The terms of office of Mr. Zhang and Ms. Chen shall commence on the date of approval of the general meeting of the Company and end on the date of expiry of the term of the first session of the Board. Re-election may be carried out upon expiration of the tenure of office.

## **The biographies of Mr. Zhang and Ms. Chen are set out below:**

Mr. Zhang Jiaxin, aged 42, is currently a member of the Party committee, secretary of the disciplinary committee and director of the group office of Yangtze River Pharmaceutical Group (揚子江藥業集團), mainly responsible for disciplinary inspection, overall coordination, supervision, information collection, logistics and management of the tertiary industry units of the Yangtze River Pharmaceutical Group. Mr. Zhang joined Yangtze River Pharmaceutical Group in October 2011 and served as the director of the general management office of Yangtze River Pharmaceutical Group from 2011 to 2016; and the director of the legal and discipline committee of Yangtze River Pharmaceutical Group from 2016 to 2019; from 2019 to 2020, he served as the director of the legal affairs department of Yangtze River Pharmaceutical Group; from 2020 to 2021, he served as the director of the legal compliance department of Yangtze River Pharmaceutical Group; from November 2017 to the present, he has been serving as a member of the Party committee and secretary of the disciplinary committee of Yangtze River Pharmaceutical Group; from January 2022 to the present, he has been serving as the director of the group office of Yangtze River Pharmaceutical Group.

Mr. Zhang studied at Jilin University (吉林大學) from September 2002 to June 2011 and obtained a bachelor's degree in law, a master's degree in law and a doctoral degree in law from Jilin University in 2006, 2008 and 2011, respectively.

Ms. Chen Qingqing, aged 40, was appointed as chief financial officer, vice general manager and secretary of the Board of the Company on May 9, 2021 and joint company secretary of the Company on June 28, 2021. Ms. Chen is primarily responsible for financing activities, investor relationship, internal audit and control and corporate governance of the Group. She is also in charge of the finance and legal department. Prior to joining the Group, Ms. Chen worked in Tencent Technology (Beijing) Co., Ltd. (騰訊科技(北京)有限公司) from May 2005 to April 2008. Ms. Chen worked as a deputy finance director in Beijing Qianxiang Wangjing Technology Development Co., Ltd. (北京千橡網景科技發展有限公司), a company listed on New York Stock Exchange (ticker symbol: RENN) from January 2009 to January 2015. Ms. Chen worked as a vice president of finance in Qufenqi (Ganzhou) Information Technology Co., Ltd. (趣分期(贛州)信息技術有限公司), a company listed on New York Stock Exchange (ticker symbol: QD) from March 2015 to April 2017. From May 2017 to September 2017, Ms. Chen worked as a senior finance director in Beike Finance Holdings (Beijing) Limited (貝殼金控控股(北京)有限公司) (currently known as Beike Finance Holdings (Beijing) Limited (貝殼金科控股(北京)有限公司)), a subsidiary of KE Holdings Inc., a company listed on New York Stock Exchange (ticker symbol: BEKE). Ms. Chen worked as the chief finance officer in Shihezi Chenshang Equity Investment Partnership (Limited Partnership) (石河子市辰尚股權投資合夥企業(有限合夥)) from November 2017 to July 2020. Ms. Chen worked as a vice president in Dmall Life (China) Network Technology Co., Ltd. (多點生活(中國)網絡科技有限公司) from August 2020 to March 2021.

Ms. Chen obtained her bachelor's degree in management and her master's degree in economics from Central University of Finance and Economics (中央財經大學) in the PRC in July 2004 and December 2017, respectively. Ms. Chen also obtained her master's degree in business administration from Peking University (北京大學) in the PRC in June 2019.

The Company will enter into director service contracts with Mr. Zhang and Ms. Chen upon approval at the general meeting. Mr. Zhang will not receive remuneration from the Company as a non-executive director. Ms. Chen receives remuneration for her positions in the Company, and her remuneration of HK\$320,000 per year (before tax) as an executive director will be included in her total remuneration received from her positions in the Company.

Save as disclosed above, as of the date of this announcement, Mr. Zhang and Ms. Chen confirmed that (1) they did not hold any directorships in any other listed companies in the past three years nor did they have any other major appointments or professional qualifications; (2) they did not hold any positions in the Company or any of its subsidiaries; (3) they did not have any relationships with any directors, supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company or any of its subsidiaries; and (4) they did not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of other information on the proposed appointment of Mr. Zhang and Ms. Chen which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the proposed appointment of Mr. Zhang and Ms. Chen that need to be brought to the attention of the Shareholders.

A circular containing, among other things, the details of the above resolutions, together with a notice convening a general meeting, will be despatched to the Shareholders in due course.

By order of the Board  
**Jiangsu Recbio Technology Co., Ltd.**  
**Dr. Liu Yong**  
*Chairman*

Jiangsu Province, the PRC, March 20, 2023

*As at the date of this announcement, the Board comprises Dr. Liu Yong as the chairman of the Board and an executive director, Dr. Chen Jianping and Mr. Li Bu as executive directors, Dr. Hong Kunxue, Dr. Zhou Hongbin and Dr. Feng Tao as non-executive directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Professor Yuen Ming Fai as independent non-executive directors.*